Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
NBIX

Neurocrine Biosciences Inc

NBIX

117.28USD-2.72 (-2.27%)Market Closed
Watchlist

Market Summary

USD117.28-2.72
Market Closed
-2.27%

NBIX Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)

NBIX Stock Price

View Fullscreen

NBIX RSI Chart

NBIX Valuation

Market Cap

11.5B

Price/Earnings (Trailing)

60.3

Price/Sales (Trailing)

6.46

EV/EBITDA

41.08

Price/Free Cashflow

29.94

NBIX Price/Sales (Trailing)

NBIX Profitability

EBT Margin

14.12%

Return on Equity

9.54%

Return on Assets

6.71%

Free Cashflow Yield

3.34%

NBIX Fundamentals

NBIX Revenue

Revenue (TTM)

1.8B

Revenue Y/Y

28.59%

Revenue Q/Q

10.18%

NBIX Earnings

Earnings (TTM)

191.0M

Earnings Y/Y

21.31%

Earnings Q/Q

-12.98%

Price Action

Last 7 days

0.1%

Last 30 days

1.6%

Last 90 days

7.3%

Trailing 12 Months

-2.6%

How does NBIX drawdown profile look like?

NBIX Financial Health

Current Ratio

2.39

NBIX Investor Care

Shares Dilution (1Y)

2.51%

Diluted EPS (TTM)

1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.6B1.7B1.8B0
20221.2B1.3B1.4B1.5B
20211.0B1.0B1.1B1.1B
2020886.8M1.0B1.0B1.0B
2019518.6M605.1M675.5M788.1M
2018232.7M323.3M414.3M451.2M
201751.7M88.3M125.0M161.6M
201615.0M15.0M15.0M15.0M
201500019.8M
20140000
201340.6M28.0M15.5M2.9M
201276.2M74.6M42.3M53.1M
201145.3M52.8M80.0M77.4M
201010.6M18.2M25.9M33.5M
20090003.0M

Latest Insider Trading transactions for NBIX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
lyons gary a
acquired
64,900
12.98
5,000
-
Dec 01, 2023
lyons gary a
sold
-583,837
116
-5,000
-
Nov 29, 2023
onyia jude
sold
-264,733
113
-2,331
chief scientific officer
Nov 27, 2023
lippoldt darin
sold
-1,225,910
112
-10,919
chief legal officer
Nov 16, 2023
sherwin stephen a
gifted
-
-
-2,750
-
Oct 02, 2023
boyer david w.
sold
-161,921
112
-1,437
chief corp. affairs officer
Sep 12, 2023
lyons gary a
acquired
64,900
12.98
5,000
-
Sep 12, 2023
lyons gary a
sold
-575,120
115
-5,000
-
Sep 01, 2023
lyons gary a
sold
-550,316
110
-5,000
-
Sep 01, 2023
cooke julie
sold
-91,406
110
-824
chief human resources officer

1–10 of 50

Which funds bought or sold NBIX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
Hudson Bay Capital Management LP
added
29.03
3,941,750
11,250,000
0.04%
Dec 06, 2023
CITIGROUP INC
reduced
-9.22
1,637,790
21,357,900
0.02%
Nov 27, 2023
TRUST CO OF VERMONT
sold off
-100
-9,996
-
-%
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-22.43
-2,514,960
31,196,300
0.02%
Nov 22, 2023
Aurora Investment Counsel
reduced
-0.92
231,896
1,505,700
1.00%
Nov 22, 2023
KBC Group NV
unchanged
-
-
2,811,000
0.01%
Nov 22, 2023
Polar Capital Holdings Plc
reduced
-13.33
1,200,000
36,562,500
0.27%
Nov 21, 2023
Walleye Capital LLC
new
-
3,455,210
3,455,210
0.01%
Nov 21, 2023
COMERICA BANK
new
-
7,418
7,418
-%
Nov 21, 2023
COMERICA BANK
added
756
17,431,700
17,491,700
0.09%

1–10 of 42

Latest Funds Activity

Are funds buying NBIX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NBIX
No. of Funds

Schedule 13G FIlings of Neurocrine Biosciences Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
janus henderson group plc
2.5%
2,415,638
SC 13G/A
Feb 09, 2023
vanguard group inc
9.72%
9,340,295
SC 13G/A
Jan 23, 2023
blackrock inc.
13.1%
12,627,403
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
4.5%
4,359,645
SC 13G/A
Feb 10, 2022
vanguard group inc
9.26%
8,787,991
SC 13G/A
Feb 10, 2022
janus henderson group plc
7.8%
7,445,839
SC 13G/A
Jan 27, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A
Jan 26, 2022
blackrock inc.
12.1%
11,476,545
SC 13G/A
Aug 10, 2021
fmr llc
-
0
SC 13G/A
Apr 12, 2021
blackrock inc.
11.7%
10,989,646
SC 13G/A

Recent SEC filings of Neurocrine Biosciences Inc

View All Filings
Date Filed Form Type Document
Dec 08, 2023
4
Insider Trading
Dec 08, 2023
4
Insider Trading
Dec 06, 2023
144
Notice of Insider Sale Intent
Dec 06, 2023
144
Notice of Insider Sale Intent
Dec 05, 2023
4
Insider Trading
Dec 01, 2023
144
Notice of Insider Sale Intent
Dec 01, 2023
4
Insider Trading
Nov 29, 2023
144
Notice of Insider Sale Intent
Nov 29, 2023
4
Insider Trading
Nov 27, 2023
144
Notice of Insider Sale Intent

NBIX Fair Value

Loading...

Peers (Alternatives to Neurocrine Biosciences Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.5B
102.8B
2.69% -12.25%
11.25
3.79
11.47% 80.74%
272.8B
59.3B
-0.63% -5.14%
17.88
4.63
0.58% -69.80%
162.5B
68.5B
-6.62% -44.42%
15.5
2.37
-31.38% -64.79%
144.0B
26.8B
-1.52% -4.93%
19.03
5.37
1.91% 10.69%
98.5B
27.4B
1.44% -10.10%
16.77
3.6
0.94% 76.21%
MID-CAP
11.0B
15.3B
7.32% 18.03%
-4.98
0.72
0.87% -71.24%
4.3B
1.6B
4.36% 1.49%
20.08
2.71
40.56% 266.27%
4.0B
4.7B
2.10% -7.72%
-978.12
0.86
5.74% 96.18%
2.7B
601.3M
24.99% 94.42%
20.1
4.52
24.02% 75.17%
2.7B
8.5B
1.81% -4.07%
-2.77
0.31
5.11% -479.13%
SMALL-CAP
1.4B
650.9M
10.34% -28.86%
-0.96
2.13
6.08% -185.21%
22.1M
-
-5.00% -65.05%
0.32
0.55
-19.54% 888.31%
15.2M
111.1M
27.41% 2089.90%
-0.96
0.14
-10.43% 84.90%
12.5M
-
39.62% -61.05%
-0.59
0.13
287.27% -145.15%
5.2M
20.0M
16.16% 1110.53%
-0.38
0.26
137.71% 66.04%

Neurocrine Biosciences Inc News

Latest updates
Yahoo Finance09 Dec 202304:05 pm6 hours ago
MarketBeat07 Dec 202302:37 pm2 days ago
BioSpace06 Dec 202308:55 am3 days ago
Marketscreener.com05 Dec 202309:02 pm4 days ago
Investing.com Australia04 Dec 202309:29 pm5 days ago
Investing.com Türkiye04 Dec 202309:25 pm5 days ago
Investing.com France04 Dec 202309:20 pm5 days ago
Investing.com Italia04 Dec 202309:20 pm5 days ago
Yahoo Finance02 Dec 202310:06 am7 days ago
Marketscreener.com01 Dec 202312:01 pm8 days ago
Nasdaq30 Nov 202308:00 am9 days ago
Investing.com27 Nov 202303:26 pm12 days ago
GuruFocus.com14 Nov 202308:00 am25 days ago
MarketWatch10 Nov 202308:00 am29 days ago
Morningstar10 Nov 202308:00 am29 days ago

Financials for Neurocrine Biosciences Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue10.2%499453420412388378311312296289237248259302237244222184138131152
Cost Of Revenue---------------2.002.002.00-1.002.002.00
Costs and Expenses-5.7%358379535309300324308348252226205176303226178-132149---
Operating Expenses------------17630322617819513214923911097.00
  S&GA Expenses-7.9%20422224318318618320115715514312910711397.0011810185.0081.0088.0069.0060.00
  R&D Expenses-----------73.00---58.00--62.0038.0039.0035.00
EBITDA Margin0.5%0.15*0.15*0.07*0.16*0.08*0.04*0.11*0.12*0.18*0.10*0.13*0.14*0.14*0.26*0.26*------
Interest Expenses-15.4%1.001.001.001.001.002.003.007.007.006.006.008.009.008.008.008.008.008.008.008.008.00
Income Taxes24.5%33.0026.00-26.7029.0029.00-6.408.00-6.508.0015.00-4.90-3061.004.002.005.005.001.00-0.50--
Earnings Before Taxes-4.9%116122-10311898.00-23.3021.00-13.8031.0058.0027.0042.00-57.1083.0039.0039.0058.0052.00-10219.0051.00
EBT Margin0.9%0.14*0.14*0.06*0.14*0.06*0.01*0.08*0.09*0.15*0.07*0.09*0.10*0.10*0.22*0.21*------
Net Income-13.0%83.0096.00-76.6089.0069.00-16.9014.00-7.3023.0042.0032.00348-57.6080.0037.0034.0054.0051.00-10218.0051.00
Net Income Margin1.5%0.11*0.11*0.04*0.10*0.04*0.01*0.06*0.08*0.42*0.35*0.38*0.39*0.09*0.20*0.20*------
Free Cashflow18.3%204173-133141101129-48.10-4.7056.0099.0083.0084.00-17.9011734.00------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets9.0%2,8482,6132,3602,3692,1432,0062,1452,0732,0171,9561,8461,7351,5031,5161,3621,3061,1801,067958993934
  Current Assets10.2%1,6501,4971,4331,4541,2061,0191,0189731,0061,1101,0851,0161,1571,146968831819749633738714
    Cash Equivalents83.3%29416010426321216327034431136835319042541518711617214778.00147201
  Inventory-9.1%29.0032.0033.0035.0037.0029.0029.0031.0026.0028.0030.0028.0021.0022.0021.0017.0011.0012.0013.0011.006.00
  Net PPE4.9%69.0066.0063.0059.0061.0067.0064.0059.0051.0050.0045.0045.0043.0045.0042.0042.0040.0040.0037.0034.0029.00
Liabilities11.3%846760675661599582753699671677641609698684662669605583548512486
  Current Liabilities18.7%69258337453848528625424622621319018761157314056511610172.0088.00456
Shareholder's Equity8.0%2,0021,8531,6851,7081,5451,4231,3911,3741,3461,2791,2061,126804831700637575484409481448
  Retained Earnings21.4%-304-387-483-406-495-564-547-635-628-651-693-725-1,073-1,015-1,095-1,132-1,166-1,220-1,271-1,177-1,195
  Additional Paid-In Capital3.0%2,3092,2422,1712,1222,0542,0001,9482,0111,9741,9291,8981,8501,8741,8421,7971,7681,7401,7031,6811,6601,645
Shares Outstanding0.6%98.0098.0098.0097.0096.0096.0095.0095.0095.0095.0094.0094.0093.0093.0093.0092.0092.0091.0091.0091.0091.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations18.0%212,000179,600-125,200143,00098,800138,100-40,5004,20061,800103,20087,30094,500-20,400118,90035,50097,50097,80064,200-112,50050,49068,917
  Share Based Compensation-30.2%47,80068,50039,90043,50043,10049,50037,00035,60037,10028,60032,90021,00026,70029,50022,80021,30020,30017,90015,80013,30013,070
Cashflow From Investing22.7%-97,300-125,900-42,100-115,600-61,30031,400-31,60023,700-126,200-90,80063,100-147,70025,20093,40033,200-166,200-85,600-30041,000-106,241-45,095
Cashflow From Financing548.3%18,8002,9008,20024,60011,400-276,4006,1001,8007,5003,00015,100-185,0005,40015,8006,00012,40013,1004,3002,6001,7525,490

NBIX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Revenues$ 498.8$ 387.9$ 1,371.9$ 1,076.7
Operating expenses:    
Cost of revenues11.26.131.215.5
Research and development142.2107.7427.5345.8
Acquired in-process research and development0.00.0143.90.0
Selling, general and administrative204.2186.3668.7569.8
Total operating expenses357.6300.11,271.3931.1
Operating income141.287.8100.6145.6
Other income (expense):    
Interest expense(1.1)(1.2)(3.5)(6.0)
Unrealized (loss) gain on equity security investments(40.1)11.1(0.6)23.6
Loss on extinguishment of convertible senior notes0.00.00.0(70.0)
Investment income and other, net15.60.237.42.8
Total other (expense) income, net(25.6)10.133.3(49.6)
Income before provision for income taxes115.697.9133.996.0
Provision for income taxes32.529.431.930.5
Net income83.168.5102.065.5
Foreign currency translation adjustments, net of tax(1.4)0.00.70.0
Unrealized gain (loss) on debt securities available-for-sale, net of tax0.8(1.8)5.5(12.3)
Comprehensive income$ 82.5$ 66.7$ 108.2$ 53.2
Earnings per share:    
Basic (in USD per share)$ 0.85$ 0.72$ 1.05$ 0.69
Diluted (in USD per share)$ 0.82$ 0.69$ 1.01$ 0.67
Weighted-average shares outstanding:    
Basic (in shares)97.995.897.595.6
Diluted (in shares)101.199.0100.698.3
Net product sales    
Revenues:    
Revenues$ 491.8$ 379.3$ 1,353.4$ 1,036.3
Collaboration revenues    
Revenues:    
Revenues$ 7.0$ 8.6$ 18.5$ 40.4

NBIX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 293.7$ 262.9
Debt securities available-for-sale801.4726.4
Accounts receivable417.8350.0
Inventories28.835.1
Other current assets108.279.1
Total current assets1,649.91,453.5
Deferred tax assets383.2305.9
Debt securities available-for-sale454.7299.4
Right-of-use assets80.887.0
Equity security investments132.8102.1
Property and equipment, net68.858.6
Intangible assets, net34.937.2
Other assets43.125.0
Total assets2,848.22,368.7
Current liabilities:  
Accounts payable and accrued liabilities503.0347.6
Convertible senior notes169.9169.4
Other current liabilities18.720.7
Total current liabilities691.6537.7
Noncurrent operating lease liabilities85.993.5
Other long-term liabilities68.629.7
Total liabilities846.1660.9
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5.0 million shares authorized; no shares issued and outstanding0.00.0
Common stock, $0.001 par value; 220.0 million shares authorized; 98.2 million and 96.5 million shares issued and outstanding, respectively0.10.1
Additional paid-in capital2,308.52,122.4
Accumulated other comprehensive loss(1.7)(7.9)
Accumulated deficit(304.8)(406.8)
Total stockholders’ equity2,002.11,707.8
Total liabilities and stockholders’ equity$ 2,848.2$ 2,368.7
NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
 CEO
 WEBSITEwww.neurocrine.com
 EMPLOYEES1350

Neurocrine Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Neurocrine Biosciences Inc? What does NBIX stand for in stocks?

NBIX is the stock ticker symbol of Neurocrine Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neurocrine Biosciences Inc (NBIX)?

As of Fri Dec 08 2023, market cap of Neurocrine Biosciences Inc is 11.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBIX stock?

You can check NBIX's fair value in chart. The fair value of Neurocrine Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neurocrine Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NBIX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neurocrine Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether NBIX is over valued or under valued. Whether Neurocrine Biosciences Inc is cheap or expensive depends on the assumptions which impact Neurocrine Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBIX.

What is Neurocrine Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, NBIX's PE ratio (Price to Earnings) is 60.3 and Price to Sales (PS) ratio is 6.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBIX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Neurocrine Biosciences Inc's stock?

In the past 10 years, Neurocrine Biosciences Inc has provided 0.285 (multiply by 100 for percentage) rate of return.